Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 1895344 with Cisplatin +/- Gemcitabine in Advanced Solid Tumors
NCT04491942Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2021
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of elimusertib in solid tumor and urothelial carcinoma (UC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Incidence of adverse events and Recommended phase 2 dose. Started Aug 2021; status: active, not recruiting.
02
Drugs
elimusertib
03
Conditions
solid tumorurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04491942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04491942.